Pfizer Inc. (NYSE:PFE) Shares Purchased by Strategic Wealth Partners Ltd.

Strategic Wealth Partners Ltd. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 22.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,234 shares of the biopharmaceutical company’s stock after purchasing an additional 3,125 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Pfizer were worth $442,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PFE shares. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $22.83 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s 50 day moving average price is $23.65 and its 200-day moving average price is $25.32. The firm has a market capitalization of $129.77 billion, a PE ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 EPS. The company’s quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.